BenzingaAugust 19, 2026 at 6:47 AM NY16 days ago
Rothschild & Co Initiates Coverage On ResMed with Neutral Rating, Announces Price Target of $230
Rothschild & Co analyst Jackson Philips initiates coverage on ResMed (NYSE:RMD) with a Neutral rating and announces Price Target of $230.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga
Companies in This Story
Related Stories
Verisk CargoNet Reports Persistent Labor Day Cargo Theft Exposure Across U.S. Freight Networks
Yahoo4 hours ago
Which dow jones stocks are moving on Friday?
ChartMill5 hours ago
Exploring the top movers within the S&P500 index during today's session.
ChartMill5 hours ago
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Yahoo5 hours ago
Sector Update: Financial
Yahoo6 hours ago